Literature DB >> 3963981

Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease.

B Nicotra, M Rivera, J I Luman, R J Wallace.   

Abstract

To determine the possible role of Branhamella (formerly Neisseria) catarrhalis as a respiratory pathogen, we screened quality sputa (defined by cellular criteria) that showed numerous gram-negative cocci on Gram's stain for the presence of B catarrhalis. In an eight-month period, 52 isolates of B catarrhalis were identified in adults attending a hospital for chest diseases. During this period B catarrhalis was the third most common potential pathogen isolated from sputa. Twenty-two patients (42%) had associated patchy bronchopneumonic or lobar infiltrates. All had negative blood cultures and a generally mild clinical course. The majority of strains (73%) of B catarrhalis produced beta-lactamase and were resistant to penicillin and ampicillin. Isolates (including beta-lactamase-producing strains) were susceptible to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole. These studies demonstrate that in patients with chronic lung disease, the presence of B catarrhalis in sputum can be suspected on the basis of a Gram's stain and may be associated with the development of new pneumonic infiltrates. Since these organisms frequently produce beta-lactamase, empiric antimicrobial therapy should include agents other than the penicillins.

Entities:  

Mesh:

Year:  1986        PMID: 3963981

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  39 in total

1.  Mechanisms to assess Gram stain interpretation proficiency of technologists at satellite laboratories.

Authors:  Erik Munson; Timothy Block; Janice Basile; Jeanne E Hryciuk; Ronald F Schell
Journal:  J Clin Microbiol       Date:  2007-08-29       Impact factor: 5.948

Review 2.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

3.  Identification and characterization of a novel outer membrane protein (OMP J) of Moraxella catarrhalis that exists in two major forms.

Authors:  John P Hays; Saskia van Selm; Theo Hoogenboezem; Silvia Estevão; Kimberly Eadie; Peter van Veelen; Jan Tommassen; Alex van Belkum; Peter W M Hermans
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

4.  Antigenic heterogeneity and molecular analysis of CopB of Moraxella (Branhamella) catarrhalis.

Authors:  S Sethi; J M Surface; T F Murphy
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

Authors:  A Verghese; D Roberson; J H Kalbfleisch; F Sarubbi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  [Smoking and lower respiratory tract infection].

Authors:  R B Brown
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 9.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  Epidemiological typing of Moraxella catarrhalis by using DNA probes.

Authors:  D Beaulieu; S Scriver; M G Bergeron; D E Low; T R Parr; J E Patterson; A Matlow; P H Roy
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.